CPG developed a permanent, non-migrating, biocompatible material suitable for percutaneous injection. In collaboration with the Massachusetts General Hospital, this hydrogel has been used to treat mitral valve regurgitation in an ovine model. Additionally, CPG has investigated the use of this formulation for urinary incontinence and gastroesophageal reflux disease (GERD). Findings published in the JACC: Cardiovascular Interventions.